title: SLC17A7 gene may be the indicator of selective serotonin reuptake inhibitor treatment response in the Chinese Han population.
abstract: Selective serotonin reuptake inhibitors (SSRIs) are widely used drugs for major depressive disorder (MDD), although the treatment outcomes vary in different people. The vesicular glutamate transporter 1 coded by SLC17A7 gene has been reported associated with MDD. According to its role in glutamate transmission, it is reasonable to consider it as a potential pharmacogenetic candidate in SSRI treatment. A total of 290 MDD patients who had been taking SSRIs for 6 weeks were recruited. Their genotypes were assessed for the presence of 4 single-nucleotide polymorphisms, which were selected from either the HapMap Chinese ethnic group or the literature report. Treatment effects were evaluated by the change rate of Hamilton Rating Scale for Depression. After the adjustment for the false discovery rate, 1 single-nucleotide polymorphism (rs74174284, false discovery rate; P = 0.032) demonstrated significant association with SSRI treatment response at week 6. Our results suggest that genetic variants in the SLC17A7 gene may be indicators of treatment response in MDD patients treated by SSRIs.
authors.affiliation: From the *Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University; †Institute for Nutritional Sciences, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences; ‡Institutes of Biomedical Sciences Fudan University; §Shanghai Institute of Mental Health, Shanghai; ∥Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan; ¶The International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University, Shanghai; and #Psychiatry Department, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Yu
authors.forename: Xiaoye
authors.initials: X
authors.lastname: Huang
authors.forename: Yanfei
authors.initials: Y
authors.lastname: Cao
authors.forename: Xingwang
authors.initials: X
authors.lastname: Li
authors.forename: Baocheng
authors.initials: B
authors.lastname: Liu
authors.forename: Fengping
authors.initials: F
authors.lastname: Yang
authors.forename: Weidong
authors.initials: W
authors.lastname: Li
authors.forename: Xinzhi
authors.initials: X
authors.lastname: Zhao
authors.forename: Guoyin
authors.initials: G
authors.lastname: Feng
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
authors.forename: Zaiquan
authors.initials: Z
authors.lastname: Dong
authors.forename: Yi
authors.initials: Y
authors.lastname: Lin
authors.forename: Xirong
authors.initials: X
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: He
authors.forename: Xueli
authors.initials: X
authors.lastname: Sun
authors.forename: Guang
authors.initials: G
authors.lastname: He
mesh_terms: D000328:Adult; D044466:Asian People / Q000235:genetics*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D050598:Vesicular Glutamate Transport Protein 1 / Q000235:genetics*; D055815:Young Adult
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors; D050598:Vesicular Glutamate Transport Protein 1; C493464:SLC17A7 protein, human